Perspective

Targeting Inflammatory Pathways: Are We Entering a New Era of Mechanism-Driven Therapeutics?

Mohammad Kordkatouli[1,2], Audrius Dulskas[3], Aryan Sateei[2,4*]

[1] Department of Genetics, Faculty of Advanced Sciences and Technology, TeMS.C, Islamic Azad University, Tehran, Iran

[2] Medicinal Plants Research Center, Go.C, Islamic Azad University, Gorgan, Iran

[3] SMK College of Applied Sciences, Vilnius, Lithuania

[4] Department of Biology, Faculty of Sciences, Go.C, Islamic Azad University, Gorgan, Iran

***Corresponding author:** Aryan Sateei: Department of Biology, Faculty of Sciences, Go.C, Islamic Azad University, Gorgan, Iran. E-mail: Aryan.sateei@iau.ac.ir

Received: March 10, 2026; **Revised:** April 19, 2026; **Accepted**: May 07, 2026; **Published online:** May 12, 2026.
Nex. Pathophysiol. Ther. J. 2026; 1:005, https://doi.org/10.22034/npt.2026.1.005

Abstract:

Inflammation is a conserved biological response essential for host defense; however, its dysregulation contributes to a broad spectrum of chronic diseases, including autoimmune, cardiovascular, metabolic, neurodegenerative, and malignant disorders. Over recent decades, advances in molecular immunology have shifted the conceptual framework of inflammation from a linear cascade to a complex, network-based regulatory system, in which therapeutic efficacy depends on precise modulation of interconnected signaling pathways rather than broad immunosuppression. Despite the clinical success of biologics targeting tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), as well as small-molecule inhibitors such as Janus kinase (JAK) inhibitors, long-term disease control remains limited due to cytokine redundancy, compensatory signaling, and underlying disease heterogeneity. Intracellular signaling hubs such as nuclear factor-κB (NF-κB) and innate immune complexes including the NLRP3 inflammasome further illustrate the challenge of targeting central regulatory nodes that are simultaneously essential for physiological immune homeostasis. This commentary emphasizes that inflammatory diseases should be understood as emergent properties of adaptive immune networks rather than isolated molecular events. Mechanistic and translational relevance of this perspective lies in integrating cytokine signaling, intracellular pathways, and inflammasome biology within a systems-level framework that explains both therapeutic success and failure of current interventions. Such an integrated view highlights the limitations of single-target strategies and supports a shift toward network-informed and patient-specific approaches. Future therapeutic development will likely depend on causal network modeling, multi-omics integration, and biomarker-guided stratification to enable precision immunomodulation. This paradigm shift from pathway-centric inhibition to dynamic regulation of immune networks may provide more durable and mechanistically grounded strategies for the treatment of chronic inflammatory diseases.

Keywords: Inflammation; Cytokine signaling networks; NF-κB signaling pathway; NLRP3 inflammasome; Janus kinase (JAK) inhibitors; Systems biology and precision medicine



Graphical Abstract: From Inflammatory Pathways to Network-Level Immunomodulation: A Mechanistic Framework for Precision Anti-Inflammatory Therapeutics. The paradigm has shifted from classical cytokine-centered inflammation models to an integrated systems biology framework, where key nodes such as TNF-α, IL-6, NF-κB signaling, and the NLRP3 inflammasome function within interconnected regulatory networks driving chronic inflammatory disease. This network-based understanding underpins modern therapeutic strategies, including biologics, JAK inhibitors, and pathway-specific modulators, and is further enhanced by multi-omics integration and patient stratification approaches enabling precision immunomodulation and rational drug design.

Introduction

Inflammation is an evolutionarily conserved biological response that protects the host against infection and tissue injury (1). However, a key conceptual shift in recent years is the recognition that inflammatory signaling is not merely a protective program, but a highly interconnected regulatory network that, when dysregulated, becomes a central driver of chronic disease across multiple organ systems, including autoimmune,

cardiovascular, metabolic, neurodegenerative, and malignant disorders (2). This transition has reframed inflammation from a linear cascade model toward a systems-level network biology paradigm, in which therapeutic success depends on precise mechanistic intervention rather than broad immunosuppression (3).

Historically, anti-inflammatory pharmacotherapy relied largely on agents with broad Historically, anti-inflammatory pharmacotherapy has relied on broadly acting immunosuppressive agents such as corticosteroids and NSAIDs (4). While clinically effective in symptom control, their lack of pathway specificity highlights a fundamental limitation of earlier therapeutic paradigms: suppression of inflammatory output without mechanistic discrimination between protective and pathological immune responses (5). This limitation underscores why long-term disease modification has remained elusive in many chronic inflammatory conditions (1, 2).

A major advance in mechanistic immunology has been the identification of cytokine networks as central nodes of inflammatory regulation. Tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) are not isolated mediators but interconnected amplifiers within broader signaling circuits that govern immune cell recruitment, endothelial activation, and tissue remodeling (1, 6). Importantly, although therapeutic blockade of these cytokines has validated their causal role in disease pathogenesis, clinical experience also reveals a key mechanistic limitation: cytokine redundancy and compensatory signaling often constrain the durability of single-target interventions, indicating that inflammation is not governed by linear hierarchy but by adaptive network resilience (1, 5, 7).

The success of TNF-α and IL-6 targeted biologics represents a paradigm shift toward mechanism-based therapy; however, their clinical impact also exposes an important translational gap. Not all patients respond uniformly, and loss of response over time suggests that inflammatory disease is mechanistically heterogeneous rather than uniformly cytokine-dominant. This observation highlights the need to move beyond single-cytokine targeting toward patient-specific inflammatory network profiling, which better reflects the complexity of immune-mediated disease and may improve therapeutic stratification and long-term outcomes (1, 5-7).

At the intracellular level, NF-κB signaling functions as a central integrator of inflammatory stimuli (8). Yet, despite its position as a master regulator, direct therapeutic targeting of NF-κB has proven challenging due to its ubiquitous role in homeostatic immunity (7, 8). This paradox—centrality in disease versus indispensability in physiology—represents a recurring barrier in inflammatory drug development and emphasizes the need for context-selective modulation rather than global inhibition (9, 12).

Similarly, the NLRP3 inflammasome illustrates how innate immune sensing complexes contribute to chronic inflammatory pathology through persistent activation of IL-1β and IL-18 signaling axes (6, 7, 11). However, emerging evidence suggests that inflammasome activation is not merely a downstream effector event but is tightly coupled to metabolic and stress-response pathways (11, 12). This positions inflammasomes as metabolic-immune interface nodes, rather than isolated inflammatory triggers (11, 12).

The expansion of Janus kinase (JAK) inhibitors has further reinforced the concept that intracellular signaling hubs can be pharmacologically tractable (13, 14). Nevertheless, their broad interference with multiple cytokine pathways raises an important mechanistic trade-off between efficacy and immune suppression, again highlighting the tension between network-level targeting and pathway selectivity (7, 13, 14).

Recent advances in multi-omics technologies have transformed inflammatory disease research from reductionist pathway analysis to integrated systems-level mapping (15, 16). However, a key unresolved challenge remains: while omics approaches generate extensive molecular signatures, their translation into actionable mechanistic stratification for therapy selection is still limited (15, 17). Bridging this gap will require moving from descriptive biomarker identification toward causal network inference and predictive mechanistic modeling (18).

Taken together, these findings suggest that the future of anti-inflammatory therapy will not be defined by single-pathway inhibition, but by integrated modulation of interconnected signaling networks (19, 20). A critical unmet need is the development of frameworks that combine mechanistic biomarkers, systems biology models, and therapeutic response dynamics to enable true precision immunomodulation (3, 19, 20).

In conclusion, inflammatory disease should be viewed not as dysregulation of individual mediators, but as emergent dysfunction of adaptive signaling networks (21-23). Therapeutic progress will depend on shifting from cytokine-centric intervention strategies to systems-level mechanistic control of immune network behavior (21-23). Continued integration of molecular immunology, computational systems biology, and translational pharmacology will be essential to achieve durable and patient-specific control of inflammatory diseases (22-24).

Mechanistic and Translational Relevance

This commentary addresses a fundamental gap in contemporary inflammatory disease research: the disconnect between well-characterized molecular mediators of inflammation and their effective translation into durable, patient-specific therapeutic strategies. While cytokine signaling, intracellular pathways such as NF-κB, and inflammasome activation have been extensively validated as causal contributors to disease pathogenesis, their therapeutic exploitation has revealed a persistent limitation—biological redundancy and network-level compensatory mechanisms that reduce long-term efficacy of single-target interventions.

From a mechanistic perspective, this work integrates inflammation as an emergent property of interconnected signaling networks rather than isolated linear cascades. By framing TNF-α, IL-1, and IL-6 not as independent drivers but as nodal amplifiers within adaptive immune circuits, it highlights the systems-level organization of inflammatory pathology. This perspective is further reinforced by the dual role of NF-κB as both a central inflammatory integrator and an essential homeostatic regulator, explaining the translational challenges encountered in direct pathway inhibition.

Importantly, this analysis extends beyond molecular description by emphasizing the mechanistic basis of therapeutic failure and partial response observed with current biologics and small-molecule inhibitors, including TNF inhibitors, IL-6 receptor antagonists, and JAK inhibitors. These limitations are interpreted not as drug inefficacy, but as evidence of underlying disease heterogeneity and dynamic network resilience within inflammatory systems.

Translationally, the commentary underscores a shift toward precision immunomodulation, where therapeutic strategies are informed by patient-specific inflammatory network profiling rather than single biomarker targeting. Integration of multi-omics technologies, systems biology modeling, and causal network inference is proposed as a framework to bridge mechanistic understanding with clinical decision-making. This approach aligns with emerging precision medicine paradigms aimed at stratifying patients based on pathway activity states, immune network architecture, and predictive biomarker signatures.

Collectively, this perspective provides a conceptual bridge between molecular immunology and therapeutic innovation, reinforcing the principle that effective anti-inflammatory therapy requires modulation of network behavior rather than isolated pathway suppression. This systems-level mechanistic framing is expected to guide future development of combination therapies, adaptive treatment strategies, and biomarker-driven clinical trials in inflammatory diseases.

Conflict of Interests

The author declares that there is no conflict of interest.

Acknowledgement

The authors would like to express their sincere gratitude to all individuals who contributed to and supported this research, as well as to Islamic Azad University, Iran, for its valuable support and encouragement.

Reference

1. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204–7218. doi:10.18632/oncotarget.23208.

2. Pervin M, de Haan JB. Dysregulated redox signaling and its impact on inflammatory pathways, mitochondrial dysfunction, autophagy and cardiovascular diseases. Antioxidants. 2025;14(11):1278. doi:10.3390/antiox14111278.

3. Li J, Huang C, Tang P, Wu R, Wu Q, Zhang C. The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications. Journal of Hematology & Oncology. 2026 Feb 11. doi:10.1186/s13045-026-01780-z.

4. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. doi:10.1016/j.bcp.2020.114147.

5. Chen X, Liu K, Liu B, et al. Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases. J Hematol Oncol. 2025;19(1):1. doi:10.1186/s13045-025-01769-0.

6. Saeidi R, Veysizadeh M, Kordkatouli M. Effect of melatonin on immune system enhancement and pediatric infections: A systematic review. Immunoregulation. 2024;7(1):–. doi:10.32598/Immunoregulation.7.11.

7. Khaiboullina S. The Role of Cytokines in Disease. International Journal of Molecular Sciences. 2026 Jan 15;27(2):876. doi:10.3390/ijms27020876.

8. Li Y, Jiang H, Chen R, Huang H, Ding S. NF-κB Signaling as a Central Driver of Cancer Cachexia. Cancers. 2026 Feb 9;18(4):557. doi:10.3390/cancers18040557.

9. Oliveira-Costa JF, Prasad A. Editorial: Anti-inflammatory drug development focusing on immune mediated diseases. Front Pharmacol. 2024;15:1413141. doi:10.3389/fphar.2024.1413141.

10. Kremenevski I, Sander O, Sticherling M, Raithel M, LastName FM. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 2022;119(6):88–95. doi:10.3238/arztebl.m2022.0067.

11. Blevins HM, Xu Y, Biby S, et al. The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14:879021. doi:10.3389/fnagi.2022.879021.

12. Wang Z, Zhang S, Xiao Y, et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev. 2020;2020:4063562. doi:10.1155/2020/4063562.

13. Hindmarch DC, Malashanka S, Shows DM, et al. Janus kinase inhibitors differentially inhibit specific cytokine signals in inflammatory bowel disease. J Crohns Colitis. 2024;18(4):628–637. doi:10.1093/ecco-jcc/jjad173.

14. Belančić A, Sener S, Sener YZ, et al. Effects of Janus kinase inhibitors on rheumatoid arthritis pain: Clinical evidence and mechanistic pathways. Biomedicines. 2025;13(10):2429. doi:10.3390/biomedicines13102429.

15. Liu Y, Gao F, Cheng Y, et al. Applications and advances of multi-omics technologies in gastrointestinal tumors. Front Med (Lausanne). 2025;12:1630788. doi:10.3389/fmed.2025.1630788.
16. Mohr AE, Ortega-Santos CP, Whisner CM, et al. Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496. doi:10.3390/biomedicines12071496.
17. Wang NN, Cao F, Zhang LH, et al. Multi-omics: a bridge connecting genotype and phenotype for epilepsy? Biomark Res. 2025;13:86. doi:10.1186/s40364-025-00798-8.
18. Tanaka M. Parkinson's disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells. 2025;14(15):1161. doi:10.3390/cells14151161.
19. Gong Y, Lin W, Fang X, et al. Advances in cellular immune theranostic approaches for glioblastoma: current trends and future directions. Cancer Innov. 2025;4(4):e70018. doi:10.1002/cai2.70018.
20. Zhang L, Chen K, Li S, Liu S, Wang Z. A Novel Integrative Framework for Depression: Combining Network Pharmacology, Artificial Intelligence, and Multi-Omics with a Focus on the Microbiota–Gut–Brain Axis. Current Issues in Molecular Biology. 2025 Dec 18;47(12):1061. doi: 10.3390/cimb47121061
21. Nie J, Zhou L, Tian W, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Target Ther. 2025;10(1):112. doi:10.1038/s41392-025-02178-y.
22. Scotece M, Conde-Aranda J. Inflammation in health and disease: new insights and therapeutic avenues. Int J Mol Sci. 2022;23(15):8392. doi:10.3390/ijms23158392.
23. Donniacuo A, Mauro A, Cardamone C, et al. Comprehensive profiling of cytokines and growth factors: pathogenic roles and clinical applications in autoimmune diseases. Int J Mol Sci. 2025;26(18):8921. doi:10.3390/ijms26188921.
24. Ametaj BN. Ametaj BN. The Keto–Inflammatory Network: From Systems Biology to Biological Code. Dairy. 2026 Feb 16;7(1):19. 2026;7(1):19. doi:10.3390/dairy7010019.